Dayvigo Complete Drug-Drug Interaction Profile

How Lemborexant Works: The Mechanism Behind Its Interactions

Lemborexant blocks both orexin OX1 and OX2 receptors competitively. Orexin (also called hypocretin) is a wake-promoting neuropeptide produced in the lateral hypothalamus. Blocking both receptor subtypes suppresses wakefulness drive without producing broad GABA-ergic inhibition, which is why the interaction profile differs meaningfully from benzodiazepines and Z-drugs.

OX1 vs. OX2 Receptor Selectivity

Lemborexant binds OX1R and OX2R with Ki values of 6.2 nM and 2.6 nM, respectively, showing roughly 2.4-fold selectivity for OX2R. OX2R blockade is considered the primary driver of sleep onset. This receptor pharmacology means that lemborexant does not potentiate GABA-A directly, so its pharmacodynamic interactions are narrower than benzodiazepines but still clinically meaningful whenever other CNS-active drugs are co-prescribed.

Why CYP3A4 Dominates the Interaction Profile

After oral absorption, lemborexant undergoes extensive hepatic first-pass metabolism. The FDA prescribing information identifies CYP3A4 as the dominant clearance enzyme, with CYP3A5 contributing minimally. The FDA label states that in a dedicated drug interaction study, co-administration with itraconazole 200 mg (a strong CYP3A inhibitor) increased lemborexant AUC by approximately 4-fold. That magnitude of exposure increase is the quantitative basis for the contraindication. No other metabolic enzyme, including CYP2C9, CYP2D6, or CYP1A2, contributes meaningfully to lemborexant clearance.

CYP3A4 Inhibitor Interactions: Contraindications and Dose Adjustments

This is the single most consequential category of interactions for lemborexant. CYP3A inhibitors slow clearance, raising plasma concentrations, prolonging sedation, and increasing next-morning impairment risk.

Strong CYP3A Inhibitors: Contraindicated

The FDA contraindication covers any drug classified as a strong CYP3A inhibitor. The prescribing information lists itraconazole, clarithromycin, ritonavir-boosted regimens, and similar agents as contraindicated co-medications. The itraconazole study showed a roughly 4-fold AUC increase; even starting at the 5 mg dose, that exposure would exceed the therapeutic range validated in SUNRISE-1 and SUNRISE-2.

Common strong CYP3A inhibitors to screen for include:

• Azole antifungals: itraconazole, voriconazole, posaconazole, ketoconazole
• Macrolide antibiotics: clarithromycin, telithromycin (not erythromycin, which is moderate)
• HIV protease inhibitors: ritonavir, cobicistat-boosted regimens, lopinavir/ritonavir
• Nefazodone (antidepressant with strong CYP3A inhibition)

Moderate CYP3A Inhibitors: Dose Reduction Required

For moderate inhibitors such as fluconazole, diltiazem, verapamil, erythromycin, and grapefruit juice consumed in substantial quantities, the FDA recommends reducing lemborexant to a maximum of 5 mg per night. A dedicated pharmacokinetic study with fluconazole 200 mg (a moderate CYP3A and CYP2C9 inhibitor) increased lemborexant AUC approximately 4-fold as well, which prompted the same dose-capping approach. Clinicians should note that fluconazole's inhibition magnitude is surprisingly comparable to itraconazole for lemborexant specifically, possibly because of additional CYP2C9-mediated metabolite pathways.

Grapefruit and grapefruit juice contain furanocoumarins that irreversibly inhibit intestinal CYP3A4. Animal and human pharmacokinetic data confirm that food-drug interactions with CYP3A substrates can be clinically significant. Patients prescribed lemborexant 10 mg should avoid grapefruit; those already on 5 mg should be counseled that consistent high-volume grapefruit consumption may still warrant clinical monitoring.

Weak CYP3A Inhibitors

Weak inhibitors (fluvoxamine, cimetidine, ranitidine at higher doses) are not formally contraindicated. No dedicated studies have been published with weak CYP3A inhibitors and lemborexant. Clinical judgment is warranted; if a patient is elderly or has hepatic impairment, the combined exposure increase may be relevant even from a weak inhibitor.

CYP3A Inducer Interactions: Contraindicated Class

Strong and moderate CYP3A inducers accelerate lemborexant metabolism to the point where therapeutic plasma levels may not be achievable.

Strong CYP3A Inducers

Rifampin (rifampicin) is the canonical strong inducer. In a pharmacokinetic study, rifampin decreased lemborexant AUC by approximately 88%, essentially abolishing therapeutic exposure. Other strong inducers subject to the same contraindication include carbamazepine, phenytoin, phenobarbital, primidone, and St. John's Wort (Hypericum perforatum). St. John's Wort deserves particular mention because patients may not report it unprompted; a direct question during medication reconciliation is warranted.

Moderate CYP3A Inducers

Efavirenz, bosentan, nafcillin, and modafinil are moderate CYP3A inducers. The FDA extends the contraindication to moderate inducers because even a 50-to-70% drop in AUC would leave lemborexant below the minimum effective concentration established in SUNRISE-1. SUNRISE-1 (N=291) demonstrated that the 10 mg dose was required for statistically significant improvement in subjective sleep onset latency vs. Placebo at Week 1 (P<0.001). A drug that halves or more that exposure forfeits efficacy.

CNS Depressants: Pharmacodynamic Additive Interactions

Even when lemborexant plasma levels are unaffected, co-administration with other CNS depressants produces additive sedation, respiratory depression risk, and psychomotor impairment.

Alcohol

Alcohol's pharmacodynamic interaction with lemborexant is not primarily CYP-mediated. A dedicated alcohol interaction study showed that co-administration of lemborexant 10 mg with 0.6 g/kg ethanol increased next-morning impairment (as measured by the Digit Symbol Substitution Test) compared to either agent alone. The FDA label carries an explicit warning. Patients should be counseled to avoid alcohol on nights when lemborexant is taken.

Benzodiazepines and Z-Drugs

Co-prescribing lemborexant with any benzodiazepine or Z-drug (zolpidem, eszopiclone, zaleplon) is generally not recommended. The American Academy of Sleep Medicine (AASM) clinical practice guideline on chronic insomnia treatment notes that combining hypnotic agents increases adverse event risk without established incremental benefit. Transitioning patients from a benzodiazepine to lemborexant requires a tapering strategy rather than overlap.

Opioids

Opioid co-administration creates a real respiratory depression risk. The FDA Boxed Warning for combined opioid and CNS depressant use (including sleep aids) states that co-administration can result in profound sedation, respiratory depression, coma, and death. If lemborexant is prescribed to a patient on scheduled opioids, the lowest effective dose (5 mg) should be used, and the patient should be counseled on the warning signs of respiratory depression.

Antidepressants With Sedative Properties

Mirtazapine, tricyclic antidepressants (amitriptyline, doxepin), and trazodone all produce H1-mediated sedation. No dedicated pharmacokinetic study of these combinations with lemborexant has been published. Given that orexin antagonism and histamine-1 antagonism suppress wakefulness through overlapping but distinct pathways, additive sedation is pharmacologically predictable. Dose reduction of lemborexant to 5 mg is a reasonable precaution when one of these agents is co-prescribed at therapeutic doses.

Antihistamines (First-Generation)

Diphenhydramine, doxylamine, and hydroxyzine are often OTC or prescribed for adjunct sleep. First-generation antihistamines are also moderate CYP inhibitors in some cases and produce direct H1-mediated sedation. The combination warrants caution and explicit counseling that next-morning driving may be impaired. Data from the 2013 NHANES analysis showed that antihistamine use is prevalent enough in the U.S. Adult population that polypharmacy with sleep aids is a realistic scenario.

Hepatic Impairment: A Pseudo-Interaction That Mimics CYP Inhibition

Moderate or severe hepatic impairment (Child-Pugh B or C) reduces CYP3A activity and slows lemborexant clearance in a manner functionally similar to a moderate CYP3A inhibitor. The FDA label recommends a maximum dose of 5 mg for patients with moderate hepatic impairment and states lemborexant is not recommended in severe hepatic impairment. This means that prescribing a CYP3A inhibitor to a patient already on lemborexant 5 mg for moderate hepatic impairment may effectively reproduce a "strong inhibitor scenario," even if the drug itself is only a moderate inhibitor.

P-Glycoprotein and Transporter Interactions

Lemborexant is a P-glycoprotein (P-gp) substrate. In vitro studies submitted to the FDA during the NDA review confirmed P-gp substrate status, though in vivo clinical significance was not observed at standard doses in dedicated transporter studies. Strong P-gp inhibitors such as quinidine or cyclosporine could theoretically increase lemborexant absorption at the intestinal level. No dose adjustment is currently recommended solely for P-gp inhibition, but the interaction deserves monitoring in patients on cyclosporine for solid-organ transplant, particularly given hepatic impairment in that population.

Lemborexant is not a clinically relevant inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 at therapeutic concentrations, and it is not expected to cause drug interactions as a perpetrator via these pathways.

Interactions With Other Orexin Antagonists

Suvorexant (Belsomra) is the only other FDA-approved DORA. The prescribing information for both agents does not recommend combining them. Co-administration would be expected to produce additive OX1R and OX2R blockade with no therapeutic advantage and increased risk of complex sleep behaviors, excessive daytime somnolence, and sleep paralysis. No clinical study has evaluated the combination.

Complex Sleep Behaviors and Drug Interactions That Increase Risk

Complex sleep behaviors, including sleepwalking, sleep-driving, and sleep eating, are a class-level risk for all hypnotics. The FDA issued a Boxed Warning in April 2019 covering complex sleep behaviors for eszopiclone, zaleplon, and zolpidem, and the Dayvigo label carries a similar warning. Any drug interaction that raises lemborexant exposure above the therapeutic range tested in SUNRISE-1 and SUNRISE-2 may increase this risk. That is a second reason, beyond pharmacokinetic prediction alone, why CYP3A inhibitor co-administration is contraindicated.

Interactions in Special Populations

Elderly Patients (Age 65 and Older)

Age-related reductions in CYP3A4 activity mean that pharmacokinetic interactions may be more pronounced in older adults. A population pharmacokinetic analysis of SUNRISE-2 data (N=949) found that age was not a statistically significant covariate on lemborexant clearance, but individual variability was higher in the 65-plus subgroup. The practical implication: starting at 5 mg in older adults and being especially cautious with any CYP3A inhibitor co-prescription makes clinical sense even when the interaction alone might only trigger a moderate warning.

Patients With Narcolepsy

Lemborexant is not approved for narcolepsy. Orexin neurons are severely depleted in narcolepsy type 1. A JAMA Neurology study examining DORA pharmacology in narcolepsy models found that blocking residual OX2R activity in narcolepsy type 1 patients theoretically worsens cataplexy. Patients who are inadvertently prescribed lemborexant while on sodium oxybate or pitolisant for narcolepsy represent an interaction scenario with both pharmacodynamic overlap and risk of worsening disease.

Practical Prescribing Framework: Interaction Risk by Co-Medication Class

The table below summarizes interaction severity and the required clinical action.

| Co-medication Class | Example Agents | Interaction Type | Required Action | |---|---|---|---| | Strong CYP3A inhibitors | Itraconazole, ritonavir, clarithromycin | PK: AUC ~4x increase | Contraindicated | | Moderate CYP3A inhibitors | Fluconazole, diltiazem, erythromycin | PK: AUC ~2-4x increase | Max 5 mg lemborexant | | Strong/moderate CYP3A inducers | Rifampin, carbamazepine, efavirenz | PK: AUC reduced up to 88% | Contraindicated | | Alcohol | Ethanol | PD: additive CNS | Avoid; explicit counseling | | Opioids | Oxycodone, hydrocodone, fentanyl | PD: respiratory depression | Boxed Warning; use 5 mg max | | Benzodiazepines / Z-drugs | Zolpidem, lorazepam | PD: additive sedation | Avoid combination; taper strategy | | Sedating antidepressants | Mirtazapine, amitriptyline | PD: additive sedation | Consider 5 mg; counsel | | First-gen antihistamines | Diphenhydramine | PD: additive sedation | Counsel on next-morning impairment | | Other DORAss | Suvorexant | PD: additive OX blockade | Not recommended | | Moderate hepatic impairment | N/A (disease state) | PK: reduced clearance | Max 5 mg |

Efficacy Context: Why Getting the Dose Right Matters

Dose matters because the efficacy signal in lemborexant's key trials was dose-dependent. SUNRISE-1 (N=291) randomized adults with insomnia disorder to lemborexant 5 mg, 10 mg, or placebo for 30 nights. At night 1, both doses significantly reduced subjective sleep onset latency vs. Placebo; at later time points, the 10 mg dose showed consistently larger effect sizes on wake after sleep onset (WASO) and sleep efficiency. Any interaction that reduces AUC by 50% or more, or that forces a mandatory step-down from 10 mg to 5 mg, may therefore result in subtherapeutic response for some patients.

SUNRISE-2 (N=949) extended the efficacy and safety observation to 12 months. At 6 months, lemborexant 10 mg produced a 40.5-minute reduction in subjective WASO vs. A 26.5-minute reduction with zolpidem tartrate extended release 6.25 mg (P<0.05). That comparative advantage is fragile if CYP3A inducers or inhibitors are co-prescribed and dose adjustments are not made.

The AASM insomnia guideline states: "We suggest that clinicians use CBT-I as the initial treatment for chronic insomnia in adults (GRADE: strong recommendation)" and positions pharmacotherapy, including DOARs, as an adjunct or alternative when CBT-I is unavailable or insufficient. The guideline's framing means that prescribers should make lemborexant work as well as possible within its pharmacological window; managing drug interactions correctly is part of that responsibility.

The Beers Criteria 2023 update from the American Geriatrics Society notes that all orexin receptor antagonists should be used with caution in older adults due to increased fall and motor vehicle crash risk, particularly with CNS depressant combinations.

Next-Morning Impairment: The Clinical Endpoint of Interaction Mismanagement

Next-morning driving impairment is the most measurable downstream consequence of drug interactions that raise lemborexant exposure. In a dedicated driving simulation study (PMID 32040284), lemborexant 10 mg produced statistically non-inferior next-morning driving vs. Placebo at 8 hours post-dose, whereas zolpidem 6.25 mg extended-release did not meet that non-inferiority threshold. That advantage collapses if CYP3A inhibitors raise AUC by 4-fold, extending the effective half-life well past 8 hours. Patients should be warned explicitly that any CYP3A inhibitor started after lemborexant may convert an acceptable next-morning profile into a hazardous one.

The FDA guidance on drug-drug interaction studies for sedative-hypnotics recommends that sponsors evaluate driving impairment as a pharmacodynamic endpoint when AUC interactions exceed 2-fold. A 4-fold AUC increase from strong CYP3A inhibition more than meets that threshold.